Get the Stockscreener App
1.56
2.50%
-0.04
Pre-market:
1.55
-0.01
-0.64%
MAIA Biotechnology Inc stock is traded at $1.56, with a volume of 193.69K.
It is down -2.50% in the last 24 hours and down -12.36% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.60
Open:
$1.57
24h Volume:
193.69K
Relative Volume:
0.47
Market Cap:
$47.28M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.1304
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+5.41%
1M Performance:
-12.36%
6M Performance:
-16.58%
1Y Performance:
-43.68%
1-Day Range:
$1.50
$1.59
1-Week Range:
$1.46
$1.73
52-Week Range:
$1.40
$3.742
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.56 | 49.23M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology Secures European Patent for Cancer Therapy - MSN
MAIA Biotechnology, Inc. Grants European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - MarketScreener
Custom watchlist performance reports with MAIA Biotechnology Inc.Weekly Gains Report & Community Trade Idea Sharing - Newser
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - GlobeNewswire
MAIA's New Cancer Drug Patent Combines Telomere Targeting with Immunotherapy for Better Results - Stock Titan
Price Clustering Detected in MAIA Biotechnology Inc. StockJuly 2025 Snapshot & Safe Entry Point Alerts - 선데이타임즈
Strategies to average down on MAIA Biotechnology Inc.Predicted Market Direction Based on Momentum - Newser
MAIA Biotechnology Inc. stock trend forecast [2025 Key Highlights]Free Long-Term Growth Portfolio Plans - Newser
What is MAIA Biotechnology Inc.’s market positionTrade Picks with 3x Upside - kangso.co.kr
Candlestick signals on MAIA Biotechnology Inc. stock todayEntry Confirmation Using Short-Term Forecasting - Newser
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
MAIA Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
When is the best time to exit MAIA Biotechnology Inc.Asset Safety Selection Using Quantitative Analysis - Newser
Regression analysis insights on MAIA Biotechnology Inc. performancePredictive Short-Term Market Reversal Alerts - Newser
What machine learning models say about MAIA Biotechnology Inc.Free ROI Driven Equity Selection With Safety - Newser
Technical analysis overview for MAIA Biotechnology Inc. stockCapital Growth Summary Over Five Years - Newser
Moving Average Trends for MAIA Biotechnology Inc. Stock: What They IndicateWeekly Trend Watch with Market Signals - Newser
Published on: 2025-08-04 17:15:59 - metal.it
How volatile is MAIA Biotechnology Inc. stock compared to the marketBuild wealth with proven stock investing tactics - Jammu Links News
What analysts say about MAIA Biotechnology Inc. stockMaster stock selection with insider knowledge - Jammu Links News
Why is MAIA Biotechnology Inc. stock attracting strong analyst attentionGet timely alerts on top market movers - Jammu Links News
What institutional investors are buying MAIA Biotechnology Inc. stockAchieve consistent profits with smart trading - Jammu Links News
Should I hold or sell MAIA Biotechnology Inc. stock in 2025Maximize gains with strategic stock entries - Jammu Links News
What makes MAIA Biotechnology Inc. stock price move sharplyIdentify winners with top-tier analysis - Jammu Links News
MAIA Biotechnology Inc. Stock Analysis and ForecastMaximize your portfolio’s growth potential - Jammu Links News
What catalysts could drive MAIA Biotechnology Inc. stock higher in 2025Unlock powerful insights from market experts - Jammu Links News
Is MAIA Biotechnology Inc. a growth stock or a value stockMaximize portfolio value with timely trades - Jammu Links News
What is the dividend policy of MAIA Biotechnology Inc. stockAchieve rapid portfolio appreciation - Jammu Links News
Is MAIA Biotechnology Inc. stock overvalued or undervaluedNavigate the market with precision tools - Jammu Links News
How does MAIA Biotechnology Inc. generate profit in a changing economyInvest confidently with real-time data analysis - Jammu Links News
MAIA Biotechnology Announces FDA Fast Track For First-in-Class Telomere-Targeting Drug In NSCLC; Latest Data In Pivotal Phase 2 THIO-101 Clinical Trial Shows Median Overall Survival Of 17.8 Months - 富途牛牛
What are analysts’ price targets for MAIA Biotechnology Inc. in the next 12 monthsBest Dividend Entry Points For Every Investor - Jammu Links News
Does MAIA Biotechnology Inc. stock perform well during market downturnsTop Growth Alerts With Proven Results - Jammu Links News
What are the latest earnings results for MAIA Biotechnology Inc.Daily Trading Picks Backed By Experts - jammulinksnews.com
Buy Signal for MAIA Biotechnology Inc. Stock Key Technical Indicators to WatchConservative Long Term Growth Plans Under Review - beatles.ru
Maia Biotechnology shares jump after FDA awards Fast Track status - MSN
Can MAIA Biotechnology Inc. recover in the next quarterTrade Timing Strategy With Technical Data Explained - metal.it
Will MAIA Biotechnology Inc. benefit from macro trendsPredictive AI Engine for Smart Investing - Newser
Key resistance and support levels for MAIA Biotechnology Inc.Real-Time AI Sentiment and Price Forecast - Newser
RSI Crosses Above 30 for MAIA Biotechnology Inc. — Reversal in SightWeekly Watchlist of High Movers Released - metal.it
Is MAIA Biotechnology Inc. stock a growth or value playSector Rotation Outlook With Historical Summary - Newser
Why MAIA Biotechnology Inc. stock attracts strong analyst attentionProfit Target Stock Opportunity Monitor Activated - metal.it
How to escape a deep drawdown in MAIA Biotechnology Inc.Asset Growth Pattern and Return Summary - Newser
Using RSI to spot recovery in MAIA Biotechnology Inc.Weekly Hot Stocks Based on Volume Flow - Newser
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Cap:
|
Volume (24h):